Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02775227 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications

Study acronym: HYPAR
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Enrollment target: 125 to 126
    • Study title expanded, about 3 words
    v4
  3. Trial status: Recruiting to Active, Not Recruitingv3 Show 4 more changesShow less
    • Enrollment target: estimated 124 to confirmed 125
    • Primary completion date changed from estimate of Dec 2018 to Jan 2019
    • Study completion date: Dec 2029
    • Site details revised
  4. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pancreatic resections carry a high risk for complications, especially pancreatic fistula. Both hydrocortisone and pasireotide have been shown to be effective in reducing complications in earlier RCTs. The aim of this study is to compare the effectiveness and safety of these two drugs in preventing complications of pancreatic surgery.
Trial Details
NCT Number NCT02775227
Lead Sponsor Helsinki University Central Hospital
Conditions
(from sponsor)		 Pancreatic Fistula, Pancreatic Neoplasms
Related terms Pancreatic Fistula, Pancreatic Neoplasms
Enrollment 126 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov